Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Immune Activation in COVID-19
NCT04815096Phase 2Recruiting
- Sponsor
- CellSight Technologies
- Start
- Apr 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [18F]fluoro-arabinofuranosyl guanine in coronavirus disease 2019 (COVID-19), sponsored by CellSight Technologies. Started Apr 2021; status: recruiting.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04815096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815096.